trial

rTMS Treatment for Positive and Negative Symptoms of Schizophrenia

NCTId NCT03413527
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Unknown
Enrollment 20 (estimated)
Sponsored by St. Joseph's Healthcare Hamilton
Primary completion 2020-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Unknown
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-02
Primary completion
2020-02
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
rTMS

Sponsors

St. Joseph's Healthcare HamiltonLead Sponsor

Investigators

1
Gary Chaimowitz, MD, FRCPCPrincipal Investigator

Sites

1 total
Hamilton, Canada

Linked catalysts

1
rTMS Treatment for Positive and Negative Symptoms of Schizophrenia — primary completion2020-02

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE2,PHASE3
Primary Completion Date
2020-02
Status
UNKNOWN
relationships
The graph out of here
drug
rTMS
drug
lead_sponsor
St. Joseph's Healthcare Hamilton
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gary Chaimowitz, MD, FRCPC
person